Moderna (MRNA) vs peers
MRNA's EV/Sales is 41.9x, compared with 7.2x at the middle of 6 peers.
Biotechnology. Updated .
| Stock | EV/Sales | Own 5-year rank |
|---|---|---|
| MRNAModerna | 41.9x | 100% |
| VRTXVertex Pharmaceuticals | 10.0x | 74% |
| ABBVAbbVie | 8.7x | 100% |
| AMGNAmgen | 7.4x | 93% |
| GILDGilead Sciences | 7.0x | 98% |
| REGNRegeneron Pharmaceuticals | 5.1x | 40% |
| INCYIncyte | 3.7x | 61% |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
EV/Sales divides enterprise value (stock market value plus debt, less cash) by revenue from the previous twelve months. The middle peer reading excludes MRNA and unavailable values.
Own 5-year rank compares each stock with its available weekly readings within the last five years. At least 26 usable weeks are required. A rank of 20% means its current multiple is above 20% of its past readings. It is not a rank against the other stocks in this table.
Dates show data updates; the latest available weekly observation can differ between stocks. Different growth rates, margins and financial risks can explain different multiples. Missing or non-positive denominators are left unranked.